OralDosed ingredientTherapeutic flag Cosmetic cross-reference

Naproxen

CAS 22204-53-1

Naproxen (CAS 22204-53-1) is a Phase 4 pharmaceutical compound with 7 bioactivity targets and 2,706 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
16
SOURCE DrugCentral / FAERS
Adverse signals
2,706
SOURCE IUPHAR / PharmGKB
PubMed IDs
6
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Naproxen
CAS Number
22204-53-1
UNII
57Y76R9ATQ
InChIKey
CMWTZPSULFXXJA-VIFPVBQESA-N
ChEMBL ID
CHEMBL154
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
black box warningdosed ingredientnatural productoraltherapeutic flag
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL154 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE ChEMBL 36 activities + assays 16 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 24006.16640625 nM 128 -
- IC50 30308.30864197531 nM 81 -
- Potency 4643.5375 nM 8 -
- Ki 565.35 nM 4 -
- IC50 50 ug 1 -
- Kd 26000 nM 1 -
Prostaglandin G/H synthase 2
Enzyme
 IC50 5.6 - Homo sapiens
Prostaglandin G/H synthase 1
Enzyme
 IC50 5.16 - Homo sapiens
Aldo-keto reductase family 1 member C2
Enzyme
 IC50 4.5 - Homo sapiens
Aldo-keto reductase family 1 member C3
Enzyme
 IC50 6.32 - Homo sapiens
Prostaglandin G/H synthase 1
Enzyme
 IC50 6.74 - Ovis aries
Prostaglandin-H2 D-isomerase
Enzyme
 IC50 4.89 - Mus musculus
Prostaglandin G/H synthase 2
Enzyme
 IC50 5.47 - Ovis aries
Prostaglandin G/H synthase 1
Enzyme
 IC50 4.96 - Bos taurus
Hormone-sensitive lipase
Enzyme
 IC50 5.92 - Rattus norvegicus
Cyclooxygenase
Enzyme
 IC50 7.22 - Rattus norvegicus
SOURCE DrugCentral 2023 / FAERS disproportionality 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Death 1026 739.681 10011906
Ankylosing spondylitis 527 709.601 10002556
C-reactive protein abnormal 823 543.127 10068559
Psoriatic arthropathy 1216 534.405 10037162
Musculoskeletal stiffness 1942 533.872 10052904
Rheumatoid arthritis 2279 507.288 10039073
Arthralgia 4396 472.364 10003239
Neutropenia 348 443.496 10029354
Drug hypersensitivity 2597 400.159 10013700
Joint swelling 2579 392.754 10023232
Fibromyalgia 915 391.665 10048439
Febrile neutropenia 222 386.428 10016288
Red blood cell sedimentation rate abnormal 437 383.239 10049186
Synovitis 1604 366.517 10042868
Pain 4945 337.644 10033371
Pharyngitis 455 336.721 10034835
Thrombocytopenia 398 312.474 10043554
Psoriasis 1016 293.766 10037153
Migraine 1005 289.526 10027599
Sepsis 440 286.952 10040047
Arthritis 1143 276.031 10003246
Pancytopenia 163 267.017 10033661
Deafness transitory 133 266.73 10011900
Disease progression 285 260.332 10061818
Pain in extremity 2558 258.49 10033425
Arthropathy 1752 251.36 10003285
Anaemia 981 246.172 10002034
Human antichimeric antibody positive 130 243.744 10069375
Body height below normal 144 242.846 10056811
Cardiac failure 171 233.813 10007554
Rheumatoid nodule 327 233.747 10048694
Gastrointestinal pain 260 231.155 10017999
Abdominal pain upper 1721 227.753 10000087
Leukopenia 112 225.5 10024384
Pneumonia 1789 225.225 10035664
Drug intolerance 2208 221.513 10061822
Polyarthritis 274 219.255 10036030
Cardiospasm 139 203.777 10007645
Gastric ulcer 433 200.541 10017822
Hypoaesthesia 1412 196.379 10020937
Grip strength decreased 341 194.754 10062556
Lip swelling 476 194.648 10024570
C-reactive protein increased 1053 193.981 10006825
Inflammation 852 192.756 10061218
Hyponatraemia 238 190.836 10021036
Drug interaction 898 185.632 10013710
Palmoplantar keratoderma 138 185.552 10033554
Pyrexia 1858 181.341 10037660
Pruritus genital 147 177.9 10037093
Obesity 443 177.725 10029883

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR ligand-target interactions 2 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
COX-1
PTGS1
 Inhibition 5.489999771118164 pIC50 9057869
COX-2
PTGS2
 Inhibition 5.599999904632568 pIC50 9057869
SOURCE PharmGKB drug-gene phenotypes 6 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

CYP2C9 (PA126) rs1057910
Allele C is associated with increased risk of gastrointestinal bleeding when treated with Antiinflammatory agents, non-steroids, celecoxib, diclofenac, ibuprofen, naproxen or piroxicam as compared to allele A.
Evidence: -; PMID 17681167
CYP2C9 (PA126) CYP2C9*1, CYP2C9*2, CYP2C9*3
CYP2C9 *3 is associated with increased risk of Gastrointestinal Hemorrhage when treated with aceclofenac, celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, naproxen or piroxicam as compared to CYP2C9 *2 + *1/*1.
Evidence: -; PMID 26544900
CYP2C9 (PA126) CYP2C9*1, CYP2C9*3
CYP2C9 *1/*3 is not associated with clearance of naproxen in men with no disease as compared to CYP2C9 *1/*1.
Evidence: -; PMID 19280158
CYP2C9 rs780801862
-
Evidence: 3; PMID 1
LST1;LTA;TNF rs1800629
Migraine without Aura
Evidence: 3; PMID 1
CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*29
-
Evidence: 4; PMID 3
SOURCE RxNorm drug names 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Naproxen 7258 SU MTHSPL
naproxen 7258 SU MTHSPL
NAPROXEN 7258 SU MTHSPL
naproxen 7258 IN RXNORM
SOURCE SIDER side-effect resource 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abdominal discomfort naproxen LLT C0232487
Abdominal discomfort naproxen PT C0232487
Abdominal distension naproxen PT C0000731
Abdominal pain naproxen LLT C0000737
Abdominal pain naproxen PT C0000737
Abdominal pain naproxen PT C0000737
Abdominal pain upper naproxen PT C0232492
Abdominal pain upper naproxen PT C0232492
Abscess naproxen LLT C0000833
Abscess naproxen PT C0000833
Abscess periodontal naproxen LLT C0031085
Acne naproxen LLT C0702166
Acne naproxen PT C0702166
Acute coronary syndrome naproxen PT C0948089
Affect lability naproxen PT C0233472
Agranulocytosis naproxen LLT C0001824
Agranulocytosis naproxen PT C0001824
Albuminuria naproxen LLT C0001925
Albuminuria naproxen PT C0001925
Alcohol abuse naproxen LLT C0085762
Alcohol abuse naproxen PT C0085762
Alkalosis naproxen LLT C0002063
Alkalosis naproxen PT C0002063
Alopecia naproxen LLT C0002170
Alopecia naproxen PT C0002170
Amblyopia naproxen LLT C0002418
Amblyopia naproxen PT C0002418
Amnesia naproxen LLT C0002622
Amnesia naproxen PT C0002622
Anaemia naproxen LLT C0002871
Anaemia naproxen PT C0002871
Anaphylactic shock naproxen LLT C0002792
Anaphylactic shock naproxen PT C0002792
Anaphylactic shock naproxen PT C0002792
Anaphylactoid reaction naproxen LLT C0340865
Anaphylactoid reaction naproxen PT C0340865
Angina pectoris naproxen LLT C0002962
Angina pectoris naproxen PT C0002962
Angiodermatitis naproxen LLT C1695895
Angiodermatitis naproxen PT C1695895
Angioedema naproxen LLT C0002994
Angioedema naproxen PT C0002994
Angiopathy naproxen LLT C0042373
Angiopathy naproxen PT C0042373
Anorectal disorder naproxen PT C0687707
Anorexia naproxen LLT C0003123
Anxiety naproxen LLT C0003467
Anxiety naproxen PT C0003467
Aortic valve stenosis naproxen LLT C0003507
Aortic valve stenosis naproxen PT C0003507
Aphthous stomatitis naproxen LLT C0038363
Aphthous stomatitis naproxen PT C0038363
Aplastic anaemia naproxen LLT C0002874
Aplastic anaemia naproxen PT C0002874
Apnoea naproxen LLT C0003578
Apnoea naproxen PT C0003578
Appetite absent naproxen LLT C1971624
Arrhythmia naproxen LLT C0003811
Arrhythmia naproxen PT C0003811
Arthralgia naproxen LLT C0003862
Arthralgia naproxen PT C0003862
Arthropathy naproxen LLT C0022408
Arthropathy naproxen PT C0022408
Asthenia naproxen LLT C0004093
Asthenia naproxen PT C0004093
Asthenia naproxen PT C0004093
Asthma naproxen LLT C0004096
Asthma naproxen PT C0004096
Bladder pain naproxen PT C0232849
Bleeding time prolonged naproxen LLT C0151529
Bleeding time prolonged naproxen PT C0151529
Blister naproxen LLT C0005758
Blister naproxen PT C0005758
Blood and lymphatic system disorders naproxen - C0851353
Blood creatinine increased naproxen PT C0235431
Blood disorder naproxen LLT C0018939
Blood disorder naproxen PT C0018939
Blood urea increased naproxen LLT C0151539
Blood urea increased naproxen PT C0151539
Blood uric acid increased naproxen PT C0235416
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Naproxen used for in pharmaceutical contexts?

Naproxen (CAS 22204-53-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Naproxen?

Naproxen has 2,706 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Death, Ankylosing spondylitis, C-reactive protein abnormal, Psoriatic arthropathy, Musculoskeletal stiffness. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Naproxen also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for NAPROXEN with EU status "permitted".

What clinical phase is Naproxen in?

Naproxen is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Naproxen?

Naproxen has 16 bioactivity rows in this page query. Rendered target entries include Prostaglandin G/H synthase 2, Prostaglandin G/H synthase 1, Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin-H2 D-isomerase.